Changes in Health Care Resource Utilization Following Initiation of Ustekinumab in Members with Inflammatory Bowel Disease in a Medicaid Population

April 11, 2022
poster for Changes in Health Care Resource Utilization Following Initiation of Ustekinumab in Members with Inflammatory Bowel Disease in a Medicaid Population
Wilson Haong, PharmD, MBA
Mckenzie Taylor, PharmD
Commonwealth Medicine
Mark Tesell, PharmD, BCPS
Commonwealth Medicine
Caroline J. Alper, MD
Commonwealth Medicine
Thomas Pomfret, PharmD, MPH, BCPS
Commonwealth Medicine
Karen Clements, ScD
Commonwealth Medicine
Bonnie C. Greenwood, PharmD, BCPS
Commonwealth Medicine
Mylissa Price, MPH, BS, RPh
Commonwealth Medicine
Diala Nicolas, PharmD, BCPS
Kimberly Lenz, PharmD, MBA, FAMCP
Commonwealth Medicine

This study aimed to identify the economic burden of inflammatory bowel disease (IBD) by comparing mean annual IBD-related medical costs and events (e.g., inpatient hospitalizations, emergency department visits, and outpatient visits) for MassHealth members before and after ustekinumab initiation. Initiation of treatment with ustekinumab was not associated with statistically significant changes in mean annual IBD-related medical costs or events in the overall study population; however, increased medical costs were observed among patients in a high- dose cohort. 

Changes in Health Care Resource Utilization Following Initiation of Ustekinumab in Members with Inflammatory Bowel Disease in a Medicaid Population